DBV Technologies (DBVT) Receivables - Net (2015 - 2020)

DBV Technologies (DBVT) posted Receivables - Net of $2.2 million for Q4 2020, up 49.72% sequentially from $1.5 million in Q4 2017.

DBV Technologies (DBVT) Receivables - Net (2015 - 2020) Analysis & Trends

DBV Technologies has reported Receivables - Net for 4 years, with the latest figure at $2.2 million in Q4 2020.

Quarterly Receivables - Net changed N/A year-over-year to $2.2 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $2.2 million (changed N/A YoY) and the FY2020 annual result came in at $2.2 million, changed N/A from the prior year.
Receivables - Net advanced to $2.2 million in Q4 2020 per DBVT's latest filing, from $1.5 million in the prior quarter.
Over five years, Receivables - Net peaked at $2.2 million in Q4 2020 and troughed at $1.4 million in Q4 2016.
A 3-year average of $1.7 million and a median of $1.5 million in 2017 frame the typical range for Receivables - Net.
The sharpest annual moves came in 2016 and 2017: Receivables - Net jumped 9470.09% in 2016, then increased 9.22% in 2017.
Over 3 years, Receivables - Net stood at $1.4 million in 2016, then gained by 9.22% to $1.5 million in 2017, then surged by 49.72% to $2.2 million in 2020.
According to Business Quant data, Receivables - Net over the past three periods registered $2.2 million, $1.5 million, and $1.4 million for Q4 2020, Q4 2017, and Q4 2016 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	DBV Technologies	6.08 Bn	5.90 Bn	-

Download Data